Mednax, Inc (NYSE:MD) has been given a consensus recommendation of “Hold” by the fourteen brokerages that are presently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a sell recommendation, nine have issued a hold recommendation and two have given a buy recommendation to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $55.44.
Several equities analysts recently issued reports on the company. Jefferies Group LLC restated a “hold” rating and set a $53.00 price objective (up from $50.00) on shares of Mednax in a research note on Thursday, July 6th. BidaskClub cut Mednax from a “hold” rating to a “sell” rating in a research note on Friday, July 28th. Mizuho reiterated a “neutral” rating and issued a $48.00 target price (down from $62.00) on shares of Mednax in a research note on Tuesday, August 1st. Robert W. Baird reiterated a “hold” rating and issued a $47.00 target price on shares of Mednax in a research note on Sunday, September 3rd. Finally, Zacks Investment Research upgraded Mednax from a “sell” rating to a “hold” rating in a research note on Wednesday, October 11th.
COPYRIGHT VIOLATION WARNING: “Brokerages Set Mednax, Inc (MD) Target Price at $55.44” was originally reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The original version of this piece can be read at https://ledgergazette.com/2017/11/13/brokerages-set-mednax-inc-md-target-price-at-55-44.html.
In other news, insider John C. Pepia sold 3,000 shares of the firm’s stock in a transaction on Tuesday, September 12th. The stock was sold at an average price of $42.85, for a total transaction of $128,550.00. Following the transaction, the insider now directly owns 35,569 shares of the company’s stock, valued at $1,524,131.65. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 2.40% of the stock is currently owned by company insiders.
Institutional investors and hedge funds have recently modified their holdings of the company. Pacer Advisors Inc. increased its holdings in shares of Mednax by 8.1% during the second quarter. Pacer Advisors Inc. now owns 1,940 shares of the company’s stock valued at $117,000 after purchasing an additional 145 shares during the period. Commonwealth Bank of Australia increased its holdings in shares of Mednax by 15.3% during the second quarter. Commonwealth Bank of Australia now owns 2,205 shares of the company’s stock valued at $132,000 after purchasing an additional 293 shares during the period. Daiwa Securities Group Inc. increased its holdings in shares of Mednax by 20.0% during the second quarter. Daiwa Securities Group Inc. now owns 3,000 shares of the company’s stock valued at $181,000 after purchasing an additional 500 shares during the period. Meiji Yasuda Asset Management Co Ltd. acquired a new position in shares of Mednax during the second quarter valued at $217,000. Finally, QS Investors LLC increased its holdings in shares of Mednax by 0.3% during the second quarter. QS Investors LLC now owns 3,812 shares of the company’s stock valued at $230,000 after purchasing an additional 12 shares during the period.
Mednax (NYSE:MD) traded up 1.82% during mid-day trading on Wednesday, reaching $44.28. 788,395 shares of the company traded hands. Mednax has a 52-week low of $40.78 and a 52-week high of $72.13. The stock has a market capitalization of $4.08 billion, a PE ratio of 14.10 and a beta of 0.37. The firm’s 50-day moving average is $43.13 and its 200 day moving average is $51.34.
Mednax (NYSE:MD) last announced its quarterly earnings data on Friday, July 28th. The company reported $0.85 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.81 by $0.04. Mednax had a return on equity of 11.89% and a net margin of 8.78%. The firm had revenue of $843.00 million for the quarter, compared to analysts’ expectations of $849.49 million. During the same period last year, the business posted $1.03 earnings per share. The firm’s revenue for the quarter was up 9.2% on a year-over-year basis. On average, equities research analysts expect that Mednax will post $3.30 earnings per share for the current year.
Mednax Company Profile
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
Receive News & Ratings for Mednax Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc and related companies with MarketBeat.com's FREE daily email newsletter.